Get the Stockscreener App
2.00
3.85%
-0.08
After Hours:
2.01
0.010
+0.50%
Vor Biopharma Inc stock is traded at $2.00, with a volume of 4.92M.
It is down -3.85% in the last 24 hours and down -9.09% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$2.08
Open:
$2.1
24h Volume:
4.92M
Relative Volume:
0.29
Market Cap:
$253.37M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-1.2195
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
-9.09%
1M Performance:
-9.09%
6M Performance:
+80.18%
1Y Performance:
+124.67%
1-Day Range:
$1.985
$2.10
1-Week Range:
$1.985
$2.51
52-Week Range:
$0.1311
$3.29
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
2.00 | 263.50M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor Biopharma Inc. stock trend forecastJuly 2025 Retail & Technical Pattern Alert System - Newser
What's Going On With Vor Bio Stock Wednesday?Vor Biopharma (NASDAQ:VOR) - Benzinga
Vor Biopharma announces board changes with three resignations and new appointment - Investing.com
Vor Biopharma Appoints Sarah Reed to Board - TipRanks
What data driven models say about Vor Biopharma Inc.’s futureJuly 2025 Earnings & Smart Investment Allocation Insights - Newser
Vor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpoint - MSN
Vor Biopharma : RemeGen's Telitacicept Meets Primary Endpoint In Phase 3 IgAN Trial In China - Nasdaq
Vor Bio, RemeGen late-stage trial of telitacicept in IgA nephropathy meets primary goal - Seeking Alpha
Vor Biopharma stock rises after collaborator’s IgAN drug hits endpoint By Investing.com - Investing.com South Africa
Vor Biopharma stock rises after collaborator’s IgAN drug hits endpoint - Investing.com
Vor Biopharma Files Prospectus for $119.7M Stock Sale - TipRanks
Vor Biopharma shareholders approve equity plan changes and reverse stock split authorization - Investing.com
Multi asset correlation models including Vor Biopharma Inc.Weekly Market Outlook & Fast Exit and Entry Trade Guides - Newser
Form 424B5 Vor Biopharma Inc. - StreetInsider
Traders Watching For Reversal Pattern in Vor Biopharma Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
Chart based analysis of Vor Biopharma Inc. trendsJuly 2025 Sentiment & AI Based Buy/Sell Signal Reports - Newser
Is This the Dip to Buy in Vor Biopharma Inc. getLinesFromResByArray error: size == 0 - kangso.co.kr
Vor Bio to Participate in Citi's Biopharma Back to School Conference - AInvest
Vor Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
Is Vor Biopharma Inc. a candidate for recovery playJuly 2025 Earnings & Technical Buy Zone Confirmations - Newser
Applying chart zones and confluence areas to Vor Biopharma Inc.IPO Watch & Low Risk Investment Opportunities - Newser
How to track smart money flows in Vor Biopharma Inc.M&A Rumor & Weekly High Conviction Ideas - Newser
Building trade automation scripts for Vor Biopharma Inc.Trade Performance Summary & Safe Entry Zone Identification - Newser
What MACD signals say about Vor Biopharma Inc.July 2025 Volume & Fast Gaining Stock Reports - Newser
What’s the MACD signal for Vor Biopharma Inc.2025 Performance Recap & Community Driven Trade Alerts - theviewers.co.kr
Best data tools to analyze Vor Biopharma Inc. stockWeekly Loss Report & High Conviction Trade Alerts - Newser
What dividend growth rate does Vor Biopharma Inc. offer2025 Major Catalysts & Risk Managed Trade Strategies - theviewers.co.kr
Strategies to average down on Vor Biopharma Inc.Portfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Building trade automation scripts for Vor Biopharma IncJuly 2025 Technicals & Daily Stock Momentum Reports - Newser
Technical Models Detect Momentum Build in Vor Biopharma Inc.2025 AllTime Highs & Verified Swing Trading Watchlists - beatles.ru
Vor Biopharma Shares Rally After Positive Clinical Results Announced - StocksToTrade
Vor Biopharma Stock Soars Amid Successful Trial Results - timothysykes.com
Key resistance and support levels for Vor Biopharma Inc.Portfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Has Vor Biopharma Inc. formed a bullish divergenceWeekly Volume Report & Fast Gain Swing Alerts - Newser
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
7 Million Stock Options: Vor Bio Awards Major Equity Package to New Biotech Talent - Stock Titan
Vor Biopharma Inc. Stock Poised for Technical ComebackJuly 2025 Trends & Accurate Technical Buy Alerts - newsimpact.co.kr
Is Vor Biopharma Inc. stock reversal real or fakeEarnings Trend Report & Scalable Portfolio Growth Methods - Newser
What institutional flow reveals about Vor Biopharma Inc.Earnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
Why Vor Biopharma Inc. stock attracts strong analyst attentionJuly 2025 EndofMonth & Reliable Trade Execution Plans - Newser
What is Vor Biopharma Inc. s 5 year growth outlook2025 Volume Leaders & Low Drawdown Momentum Ideas - thegnnews.com
Chart overlay techniques for tracking Vor Biopharma Inc.Gap Up & Consistent Profit Focused Trading Strategies - Newser
HC Wainwright Reaffirms Buy Rating for Vor Biopharma (NYSE:VOR) - Defense World
Wedbush Comments on Vor Biopharma’s Q3 Earnings (NYSE:VOR) - Defense World
Vor Biopharma Inc. stock trend outlook and recovery pathPortfolio Update Summary & Daily Technical Stock Forecast Reports - Newser
Vor Biopharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayWatch List & Accurate Technical Buy Alerts - Newser
Screener Results Flag Vor Biopharma Inc. as OversoldRate Hike & Target Return Focused Picks - newsyoung.net
Technical Charts Suggest Momentum Shift in Vor Biopharma Inc.July 2025 Selloffs & Stock Timing and Entry Methods - newsyoung.net
Vor Biopharma: HC Wainwright Raises Buy Rating to $3, PT Raised to $3. - AInvest
Machine Learning Models Forecast Vor Biopharma Inc. UptickMarket Sentiment Report & Safe Capital Preservation Plans - sundaytimes.kr
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):